biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Canadian meetings

<< Previous

Bullboard Posts

Next >>

Comment by JDavenporton Dec 11, 2022 1:08pm

143 Views

Post# 35164746

RE:Canadian meetings

Why hasn't Colwell Capital Corp. and GD, Director, Investor Relations, publicly posted the meeting schedule and locations?

GD has posted other stuff on Stockhouse. There are also other ways of informing the public, such as with a press release.

The meetings have the appearance of being by invitation only.

Is there a reluctance on the part Dr. Deborah Rathjen to face some shareholders, or perhap to answer some questions?

Are Bioasis and Colwell Capital Corp still paying the game of special shareholders having special access? Secrets? Maybe?

Everything stinks of secrets!

jd